Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.84 |
| ▸ | GAA | P10253 | 8/20 | 0.84 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.84 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.84 |
| ▸ | LMNA | P02545 | 5/20 | 0.84 |
| ▸ | HPGD | P15428 | 3/20 | 0.84 |
| ▸ | RAB9A | P51151 | 2/20 | 0.84 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.84 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.84 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.84 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.84 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.84 |
| ▸ | HTT | P42858 | 4/20 | 0.82 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.82 |
| ▸ | PKM | P14618 | 5/20 | 0.79 |
| ▸ | POLB | P06746 | 1/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.76 |
| ▸ | MEN1 | O00255 | 3/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.76 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL3426202 | 0.99 | MAPT (0.82) | MAPTGAAALDH1A1KDM4ELMNA | |
| SCHEMBL1684711 | 0.91 | MAPT (1.00) | MAPTGAAALDH1A1KDM4ELMNA | |
| Bromide SCHEMBL18040788 | 0.90 | MAPT (0.98) | MAPTGAAALDH1A1KDM4ELMNA | |
| SCHEMBL12390656 | 0.90 | MAPT (1.00) | MAPTGAAALDH1A1KDM4ELMNA | |
| SCHEMBL1684905 | 0.89 | MAPT (0.84) | MAPTGAAALDH1A1KDM4ELMNA | |
| SCHEMBL1684657 | 0.89 | MAPT (0.84) | MAPTGAAALDH1A1KDM4ELMNA | |
| SCHEMBL12427000 | 0.89 | MAPT (0.84) | MAPTGAAALDH1A1KDM4ELMNA | |
| SCHEMBL12012127 | 0.89 | MAPT (0.98) | MAPTGAAALDH1A1KDM4ELMNA | |
| Bromide SCHEMBL18040748 | 0.88 | MAPT (0.82) | MAPTGAAALDH1A1KDM4ELMNA | |
| Bromide SCHEMBL18040770 | 0.88 | MAPT (0.82) | MAPTGAAALDH1A1KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2306836-B1 | BMI-1 PROTEIN EXPRESSION MODULATORS | PTC THERAPEUTICS INC (US) | 2016-09-07 | — | — | EP | claimed |
| US-8680113-B2 | BMI-1 protein expression modulators | PTC THERAPEUTICS, INC. (US) | 2014-03-25 | — | — | US | claimed |
| US-20110190239-A1 | BMI-1 PROTEIN EXPRESSION MODULATORS | PTC THERAPEUTICS, INC. (US) | 2011-08-04 | — | — | US | claimed |
| EP-2306836-A1 | BMI-1 PROTEIN EXPRESSION MODULATORS | PTC Therapeutics, Inc. (US) | 2011-04-13 | — | — | EP | claimed |
| CN-101801942-A | Heterocyclic compounds and uses as anticancer agents | ACEA BIOSCIENCES INC | 2010-08-11 | — | — | CN | claimed |
| EP-2188271-A2 | HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS | Acea Biosciences, Inc. (US) | 2010-05-26 | — | — | EP | claimed |
| WO-2010002985-A1 | BMI-1 PROTEIN EXPRESSION MODULATORS | PTC THERAPEUTICS, INC. (US) | 2010-01-07 | — | — | WO | claimed |
| WO-2009023402-A2 | HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS | ACEA BIOSCIENCES INC. (US) | 2009-02-19 | — | — | WO | claimed |
| US-20090048271-A1 | HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS | ACEA Therapeutics, Inc. | 2009-02-19 | — | — | US | claimed |
| EP-3111956-B1 | BMI 1 PROTEIN EXPRESSION MODULATORS | PTC THERAPEUTICS INC (US) | 2019-05-08 | — | — | EP | disclosed |
| EP-3173414-A1 | HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS | ACEA Biosciences Inc. (US) | 2017-05-31 | — | — | EP | disclosed |
| EP-3173414-A1 | HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS | ACEA Biosciences Inc. (US) | 2017-05-31 | — | — | EP | disclosed |
| EP-3111956-A1 | BMI 1 PROTEIN EXPRESSION MODULATORS | PTC Therapeutics, Inc. (US) | 2017-01-04 | — | — | EP | disclosed |
| EP-2306836-B1 | BMI-1 PROTEIN EXPRESSION MODULATORS | PTC THERAPEUTICS INC (US) | 2016-09-07 | — | — | EP | disclosed |
| US-20110207751-A1 | HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS | ACEA Therapeutics, Inc. | 2011-08-25 | — | — | US | disclosed |
| US-20110207751-A1 | HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS | ACEA Therapeutics, Inc. | 2011-08-25 | — | — | US | disclosed |
| US-20110190239-A1 | BMI-1 PROTEIN EXPRESSION MODULATORS | PTC THERAPEUTICS, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| CN-101801942-A | Heterocyclic compounds and uses as anticancer agents | ACEA BIOSCIENCES INC | 2010-08-11 | — | — | CN | disclosed |
| US-20090048271-A1 | HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS | ACEA Therapeutics, Inc. | 2009-02-19 | — | — | US | disclosed |
| US-20090048271-A1 | HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS | ACEA Therapeutics, Inc. | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190239-A1 | BMI-1 PROTEIN EXPRESSION MODULATORS | BMI1, CREBBP, BAZ2A | MAPT 4026/4885GAA 3522/4885ALDH1A1 2357/4885 |
| US-20090048271-A1 | HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS | MKI67, CCNC, HCCS | MAPT 4784/4885GAA 681/4885ALDH1A1 961/4885 |
| US-20110207751-A1 | HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS | MKI67, CCNC, NUDC | MAPT 4772/4885GAA 655/4885ALDH1A1 862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.